antibody in an amount effective to decrease release of bradykinin and in an amount effective to attenuate said alterations in endothelial cell permeability in said mammal.

44. (new) The method according to claim 43, wherein said mammal is a human patient and said HBP is human HBP.

45. (new) The method according to claim 43, wherein said HBP has at least about an 80% identity with the amino acid sequence set forth in SEQ ID NO:1.

46. (new) The method according to claim 43, wherein said antibody is a human monoclonal antibody.

47. (new) The method according to claim 43, wherein said monoclonal antibody binds to an epitope of heparin-binding protein which interacts with kininogen.

48. (new) The method according to claim 43, in which the HBP antagonist is present in an amount of from about 10 mg to about 1 g per unit dosage form.

49. (new) The method according to claim 43, in which the HBP antagonist is present in an amount of about 0.1-100 mg/kg body weight.

50. (new) The method according to claim 43, in which the HBP antagonist is present in an amount of about 0.5-50 mg/kg body weight.

51. (new) The method according to claim 43, in which the HBP antagonist is present in an amount of about 1-25 mg/kg body weight.